Forma Therapeutics, Inc.

Jeff Davis

Susan Ashwell

Wei Lu

Alan Collis

Duncan Walker

Patrick F Kelly

Blythe Thomson

Lu Wei

Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)

Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

Inhibiting mutant IDH-1

Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation

Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)

Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation

Growing community of inventors

Hingham, MA, United States of America

Jeff Davis